Share

August 2013; 3 (4) Cases

Brain MRI findings in Wernicke encephalopathy

Meredith R. Wicklund, David S. Knopman
First published August 7, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e3182a1ba00
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
983

Share

Article Information

vol. 3 no. 4 363-364
DOI: 
https://doi.org/10.1212/CPJ.0b013e3182a1ba00
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published August 7, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Meredith R. Wicklund, MD and
    2. David S. Knopman, MD
  1. Meredith R. Wicklund, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. David S. Knopman, MD
    3. Scientific Advisory Boards:

    1. Lilly Pharmaceuticals, Data Safety Monitoring Board, ended 8/22/12; TauRx consultant 2012; Consultant, McGill University Alzheimer Program 9/19/12; Consultant Bluefield project (frontotemporal demantia) 2013

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Lecture, University of Toronto, March 2012 (2) Lecture, University of Pennsylvania, January 2013

    Editorial Boards:

    1. Neurology, Deputy Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Janssen Alzheimer Immunotherapy program 3/29/11: honorarium paid to my institution; (2) Merck Alzheimer program 11/5/11 paid to my institution. (3) TauRx: two presentations in clinical trial investigator meetings.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Janssen for Alzheimer clinical trial, (2) Forest Laboratories for clinical trial in FTLD with memantine, (3) Baxter Laboratories for Alzheimer Clinical trial

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer's Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. NIH R01 AG32306 FTD Neuro-imaging;Initiative. 1U01HL096917-01 ARIC Dementia Study.AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology, Mayo Clinic, Rochester, MN.
  1. Correspondence to:
    knopman{at}mayo.edu
View Full Text

Article usage

Article usage: August 2013 to July 2022

AbstractFullPdfSource
Aug 20132643885Highwire
Sep 20132371323Highwire
Oct 201380812Highwire
Nov 2013811129Highwire
Dec 201362113Highwire
Jan 201410773Highwire
Feb 20144224Highwire
Mar 20142728Highwire
Apr 20146011Highwire
May 20142742Highwire
Jun 20141712Highwire
Jul 20142303Highwire
Aug 2014901Highwire
Sep 20142323Highwire
Oct 20141503Highwire
Nov 20142203Highwire
Dec 20142200Highwire
Jan 20151000Highwire
Jan 201505123pmc
Feb 2015300Highwire
Feb 201503920pmc
Mar 20151903Highwire
Mar 201504322pmc
Apr 20151802Highwire
Apr 201504017pmc
May 20151702Highwire
May 201504436pmc
Jun 20151600Highwire
Jun 201503420pmc
Jul 20153223Highwire
Jul 201503821pmc
Aug 20151220Highwire
Aug 201505030pmc
Sep 2015804Highwire
Sep 201503018pmc
Oct 2015812Highwire
Oct 201503417pmc
Nov 2015301Highwire
Nov 201503917pmc
Dec 20151700Highwire
Dec 201502218pmc
Jan 20161302Highwire
Jan 201603213pmc
Feb 20161400Highwire
Feb 201602317pmc
Mar 2016200Highwire
Mar 201602715pmc
Apr 20161001Highwire
Apr 201602821pmc
May 20161000Highwire
May 201603614pmc
Jun 2016801Highwire
Jun 201602822pmc
Jul 2016800Highwire
Jul 20160207pmc
Aug 20162401Highwire
Aug 201603719pmc
Sep 20162700Highwire
Sep 201603618pmc
Oct 20162600Highwire
Oct 201603112pmc
Nov 20163401Highwire
Nov 201603014pmc
Dec 20162100Highwire
Dec 201603715pmc
Jan 20172101Highwire
Jan 201703112pmc
Feb 20172402Highwire
Feb 201702514pmc
Mar 20172500Highwire
Mar 20170207pmc
Apr 20171401Highwire
Apr 201773632pmc
May 20172400Highwire
May 201763028pmc
Jun 2017900Highwire
Jun 2017111917pmc
Jul 2017600Highwire
Jul 201751717pmc
Aug 20171002Highwire
Aug 201752011pmc
Sep 2017902Highwire
Sep 201763225pmc
Oct 2017800Highwire
Oct 2017133430pmc
Nov 20172200Highwire
Nov 201773228pmc
Dec 20171412Highwire
Jan 20181510Highwire
Feb 20181810Highwire
Mar 20182701Highwire
Apr 20183021Highwire
Apr 201882221pmc
May 20183701Highwire
Jun 20182500Highwire
Jun 201841614pmc
Jul 20183200Highwire
Aug 20182400Highwire
Aug 201883027pmc
Sep 20183301Highwire
Oct 20181600Highwire
Nov 20183621Highwire
Dec 20182520Highwire
Jan 20191920Highwire
Feb 20193400Highwire
Mar 20192710Highwire
Apr 20194011Highwire
May 20195121Highwire
Jun 20193711Highwire
Jul 20198510Highwire
Aug 20194201Highwire
Sep 20193020Highwire
Oct 20195610Highwire
Nov 20192821Highwire
Dec 20195000Highwire
Jan 20204831Highwire
Feb 20204200Highwire
Mar 20204520Highwire
Apr 20202822Highwire
May 20203421Highwire
Jun 20202400Highwire
Jul 20202710Highwire
Aug 20204041Highwire
Sep 20204851Highwire
Oct 20207150Highwire
Nov 20204141Highwire
Dec 20203430Highwire
Jan 20215020Highwire
Feb 20215200Highwire
Mar 20216541Highwire
Apr 20215530Highwire
May 20216420Highwire
Jun 20214130Highwire
Jul 20216450Highwire
Aug 20215560Highwire
Sep 20216420Highwire
Oct 20219021Highwire
Nov 20214750Highwire
Dec 20214811Highwire
Jan 20224620Highwire
Feb 20225440Highwire
Mar 20226342Highwire
Apr 20224430Highwire
May 20223820Highwire
Jun 20225141Highwire
Jul 20222603Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me